Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine

Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Related Videos
Hans Hammers, MD, PhD, an expert on renal cell carcinoma
Bradley McGregor, MD, an expert on renal cell carcinoma
Chung-Han Lee, MD, PhD, an expert on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Edward B. Garon, MD, MS, an expert on lung cancer